63 results about "Vimentin" patented technology

The invention relates to a detection kit for epithelial-mesenchymal transition in EB virus infected thymoma and application, the detection kit comprises a quantum dot labeled antibody E-Cadherin and a quantum dot labeled antibody Vimentin, a quantum dot is coupled with a specific antibody, a thymoma paraffin section sample is dyed through the quantum dot and the specific antibody conjugate, and the EB virus infected thymoma is obtained. The conjugate can be specifically connected with an EMT related antigen expressed in the slice, so that the quantum dots can be used for qualitative or quantitative detection of the EMT-generated thymoma cells. The quantum dots are used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of epithelial cells and mesenchymal tissues in the thymoma microenvironment is achieved, number detection and position detection can be achieved, and EMT condition evaluation is facilitated.

The invention relates to an anti-VIM nano antibody and application thereof, belongs to the technical field of biology, and aims to solve the problem of Vimentin VIM detection, and has the key points that a complementary determining region CDR of the nano antibody comprises CDR1, CDR2 and CDR3 sequences: (I): (1) the amino acid sequence of the CDR1 is shown as SEQ ID NO.27, and (2) the amino acid sequence of the CDR2 is shown as SEQ ID NO.33; and (3) the amino acid sequence of the CDR3 is shown as SEQ ID NO.39. The nano antibody and the polypeptide thereof have the effects that the nano antibody and the polypeptide thereof have very high affinity and activity, can specifically recognize and combine with VIM, can be used for capturing and detecting VIM positive cells, and can be applied to immunofluorescence analysis or immunohistochemical analysis and the like through a proper antibody labeling technology.

The invention belongs to the technical field of tumor micro-immune environments, and particularly relates to a kit for detecting a tumor micro-environment, a detection method and application, the kit comprises rare metal element labeled monoclonal antibodies, the rare metal element labeled monoclonal antibodies comprise 115In-CD20, 139La-Histone H3, 142Nd-CD56, 144Nd-CD14, 146Nd-Vimentin, 148Nd-Pan-CK, 151Eu-CD31, 156Gd-CD4, 158Gd-E-Cadrin, 159Tb-CD68, 162Dy-CD8a, 166Er-CD45, 167Er-CD15, 170Er-CD3, 171Yb-CD11c and 209Bi-alpha-SMA, and the rare metal element labeled monoclonal antibodies comprise The invention can be used for simultaneously detecting and researching the quantity, positioning and spatial topological relation of each cell component in a tumor microenvironment, and provides a multi-immunofluorescence detection kit and method for ubiquitous epithelial differentiation-derived tumors based on an imaging mass spectrum flow technique. A plurality of biomarkers can be analyzed at the same time by using multiple immunohistochemical staining and rare earth metal tag signal detection technologies, so that the aim of performing high-dimensional analysis on a tumor microenvironment is fulfilled according to cell composition, functional state and cell-cell space interaction relationship.

The invention belongs to the technical field of biological medicines, and particularly discloses application of ORM1 protein or VIM knockout adenovirus in preparation of a medicine for treating temporomandibular joint osteoarthritis (TMJOA). The invention proves that the expression of ORM1 is reduced in synovial fluid of a TMJOA patient and a unilateral anterior tooth reverse inhale model rat, and the degradation of cartilage matrix of the UAC rat can be remarkably inhibited and the progress of TMJOA can be relieved by locally injecting ORM1 protein. On the mechanism level, ORM1 is combined with waveform protein VIM to inhibit an MAPK channel, so that expression of MMP13 and MMP3 is reduced, cartilage matrix degradation is reduced, and cartilage steady state is maintained. In addition, the invention also finds that after the VIM of the rat is knocked out by using the adeno-associated virus, the progress of TMJOA, including cartilage degeneration and subchondral bone destruction, is also obviously improved. Therefore, the invention provides a new therapeutic target and a new therapeutic strategy for the TMJOA.

The invention discloses a method for enriching and identifying tumor cells with different phenotypes based on double-antibody double-particle-size magnetic beads. Epithelial cell specific cell adhesion molecules and interstitial cell specific waveform proteins are combined with magnetic beads with different particle sizes, so that epithelial, interstitial and mixed specific markers of the same cell in a living cell state can be enriched and identified at one time. The magnetic beads specifically capture target cells with different phenotypes, the captured target cells are separated in a cell sorter under the action of a magnetic field, the phenotypes of the target cells are identified according to different particle sizes of the magnetic beads adhered to the target cells, and on the basis, subsequent analysis of more markers can be further performed. According to the invention, epithelial, mesenchymal and mixed target cells can be simultaneously captured from various body fluids in a living cell state, typing and counting can be rapidly carried out through the particle sizes of the magnetic beads adhered to the surfaces of the cells, the living target cells are analyzed more accurately, and the clinical and scientific research application values are improved.

The invention provides an in-vitro anti-saccharification effect evaluation method and application thereof, and belongs to the technical field of skin saccharification resistance. A photoaging fibroblast model is adopted, after induction of an inducer, anti-saccharification evaluation is carried out by detecting the contents of collagen and waveform protein after application of a substance to be detected, and it is proved that the anti-saccharification effect of the anti-saccharification substance in the cell model is consistent with the result in human body effect evaluation; the evaluation method can be applied to screening and evaluation of anti-skin saccharification substances.

This invention belongs to the field of biomedicine and specifically relates to a method and kit for enriching circulating tumor cells (CTCs) in liver cancer using GPC3 in combination with MERTK. This method combines MERTK with traditional markers such as EpCAM, vimentin, and GPC3 to capture circulating tumor cells in liver cancer, achieving improved enrichment of CTCs. This method and its accompanying kit are widely applicable to early screening of liver cancer, postoperative recurrence monitoring, metastasis risk assessment, and personalized treatment management, and has promising prospects for clinical translation.

The invention relates to the technical field of biological medicines, in particular to application of an MAPK1IP1L gene or an MAPK1IP1L protein serving as an action target to preparation of a medicine for treating chronic kidney disease. According to the invention, the MAPK1IP1L gene overexpression (MAPK1IP1L OE) HK2 cell is constructed, and compared with a group in which the HK2 cell is not treated, the MAPK1IP1L OE has the advantage that the protein expression levels of FN, Collagen I, Vimentin and alpha-SMA are obviously reduced. Therefore, the chronic kidney disease can be improved and treated by overexpressing the MAPK1IP1L gene. Therefore, the invention relates to the application of the MAPK1IP1L gene or the MAPK1IP1L protein as the action target spot in preparation and / or screening of the medicine for treating the chronic kidney disease.

A method for the expression and / or for the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin. the method comprises applying to human skin at least one caviar extract which is capable of causing the expression and / or the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

VIM-specific nanobody and its applications belong to the field of biotechnology. To solve the problem of detecting vimentin (VIM), the key point is that the complementarity-determining regions (CDRs) of the nanobody include CDR1, CDR2, and CDR3 sequences: (I): (1) The amino acid sequence of CDR1 is shown in SEQ ID NO.27; (2) The amino acid sequence of CDR2 is shown in SEQ ID NO.33; and (3) The amino acid sequence of CDR3 is shown in SEQ ID NO.39. The effect is that the nanobody and its polypeptide of the present invention have high affinity and activity, can specifically recognize and bind to VIM, can be used for the capture and detection of VIM-positive cells, and can be applied to immunofluorescence analysis or immunohistochemical analysis through appropriate antibody labeling techniques.

The invention discloses an application of glabridin in preparation of related drugs for inhibiting epithelial-mesenchymal transition in inflammatory bowel diseases. In the epithelial-mesenchymal transformation process, epithelial cells lose cell polarity and intercellular connection, are transformed into mesenchymal cells in function and morphology, directly participate in fibroblast activation and extracellular matrix deposition and cause intestinal fibrosis, and are one of anti-fibrosis targets. According to the application of the glabrione in preparation of the medicine related to inhibition of epithelial-mesenchymal transition in the inflammatory bowel disease, provided by the invention, the expression change of epithelial cell markers Claudin-1 and E-cadherin caused by TGF-beta 1 and interstitial cell markers Vimentin, N-cadherin, Snail and alpha-SMA can be relieved, cell migration caused by TGF-beta is improved, and the epithelial-mesenchymal transition induced by TGF-beta 1 is inhibited. The research on the mechanism of action shows that by blocking a TGF-beta1 / Smad2 / 3 signal channel and inhibiting AKT1 activation and inhibition of epithelial-mesenchymal transition, the application of the compound in inhibition of epithelial-mesenchymal transition and prevention of intestinal disease related fibrosis is prompted.

The invention discloses application of METTL14 in inhibition of pituitary tumor cell proliferation and prognosis evaluation, and relates to the technical field of medicines. Experiments prove that when METTL14 is knocked out, E-cadherin can be lowered, and N-cadherin and waveform protein can be increased, so that the migration ability and proliferation and invasion ability of GH3 cells are promoted, and the tumor forming ability and in-vivo hormone level of pituitary growth hormone tumors are improved. Therefore, the METTL14 can be used for preparing a product for diagnosing or treating pituitary growth hormone adenoma, which is beneficial to theoretically researching pituitary adenoma and developing a novel targeted drug, and provides a new direction for finding a tumor marker or a new treatment strategy related to novel pituitary growth hormone adenoma diagnosis and controlling pituitary growth hormone adenoma.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

Disclosed herein are methods of detecting citrullinated polypeptides and / or citrullinated peptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in various body fluids and / or tissues of individuals with autoimmune diseases, for example the synovium of subjects with rheumatoid arthritis. Further disclosed are methods of diagnosing, treating, selecting an individual for treatment of, and monitoring the treatment of autoimmune diseases, such as rheumatoid arthritis or hidradenitis suppurativa. Kits for use with the methods described herein are also provided.

The invention discloses an antibody combination suitable for detecting DLBCL immune microenvironment by an imaging mass spectrometer, a kit and application. The antibody combination is an antibody for resisting alpha SMA, an antibody for resisting HLADR, an antibody for resisting CD20, an antibody for resisting CD56, an antibody for resisting Vimentin, an antibody for resisting CD8a, an antibody for resisting CCL17, an antibody for resisting CCR6, an antibody for resisting IL3CD123, an antibody for resisting CXCL12, an antibody for resisting BCL2, an antibody for resisting PD1, an antibody for resisting CD163, an antibody for resisting CD45RO, an antibody for resisting ICOS, an antibody for resisting GranzymeB, an antibody for resisting CXCR5, an antibody for resisting Ki67, an antibody for resisting PDL1, an antibody for resisting Bcl6, an antibody for resisting CD31, an antibody for resisting CD163, an antibody for resisting CD45RO, an antibody for resisting CD27, an And all the antibodies are marked. The DLBCL immune microenvironment can be more comprehensively and efficiently identified by using the antibody combination disclosed by the invention.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a sperm-nourishing seed jade decoction and application thereof to improvement of endometrial receptivity, the sperm-nourishing seed jade decoction is composed of 30 g of radix rehmanniae preparata, 15 g of cornus officinalis, 15 g of radix paeoniae alba and 15 g of angelica sinensis, by inhibiting the epithelial-mesenchymal transition (EMT) process, the expression of E-cadherin and beta-catenin is up-regulated, the expression of Vimentin is down-regulated, and the endometrial receptivity is improved. Therefore, the stability and integrity of endometrial epithelium are maintained, intimal thickening, gland hyperplasia and angiogenesis are promoted, and an effective treatment strategy can be provided for infertility caused by thin endometrium.

Finding that vimentin is overexpressed in cancer cells and the PLK1-induced phosphorylation of vimentin leads to tumorigenesis and cancer metastasis, the present invention suggests two methods of reducing frequency of interaction between PLK1 and vimentin as a strategy for preventing tumorigenesis and cancer metastasis by reducing the migration and infiltration of cancer, and provides an application thereof.

The invention relates to the technical field of development of retinal ischemia reperfusion injury medicines, discloses application of Vimentin in preparation of medicines for preventing and treating retinal ischemia reperfusion injury, and discloses a safer and more effective medicine for treating retinal ischemia reperfusion injury. According to the invention, the nerve protection characteristic and good biocompatibility of Vimentin are utilized, so that the side effect of the medicine is reduced, and the treatment safety is improved. In addition, the Vimentin is proved to have a good effect in the aspects of reducing oxidative stress injury and improving mitochondrial functions, and a new therapeutic target is provided for treating the retinal ischemia reperfusion injury. Meanwhile, the Vimentin disclosed by the invention can be used as a supplement or replacement of an existing treatment method, provides a new treatment choice for patients, and is particularly suitable for patients with poor response to traditional treatment medicines.

The present invention discloses the use of MAPK pathway inhibitors in anti-pathogen infection. Specifically, the present invention discloses the use of a MAPK pathway inhibitor for preparing a pharmaceutical preparation or composition for anti-pathogen infection. The MAPK pathway inhibitor of the present invention controls the reproduction of pathogens in host cells and / or reduces the number of pathogens by promoting the diffusion of vimentin in cells, thereby effectively controlling pathogen infection.

A preparation method for and use of a scopoletin-functionalized magnetic nanoprobe. The preparation method comprises steps such as preparation of amino-terminal modified nanoparticles Fe3O4@SiO2-NH2, preparation of a photoaffinity linker-scopoletin conjugate, preparation of the scopoletin-functionalized magnetic nanoprobe, etc. The method features simple and rapid operation, and eliminates the need for prior clarification of the structure-activity relationship of the active compounds, without compromising all-round contact between the active compounds and target proteins. The prepared scopoletin-functionalized magnetic nanoprobe is used for target fishing in cellular and animal models of rheumatoid arthritis. After the captured target proteins are isolated and subjected to mass spectrometry identification, a western blot experiment successfully verifies vimentin as the target protein of scopoletin on HFLS-RA cell membranes, thereby providing a novel therapeutic target for rheumatoid arthritis.

The present application belongs to the technical field of tumor detection and cell separation, and particularly relates to a kit for separating and recovering after immunocapture of circulating tumor cells, a preparation method and application. The kit comprises an immunocapture module, a dissociation and recovery module, a cell protection module and elution and supplement factor solutions. The immunocapture module adopts magnetic microspheres modified by double antibody fusion proteins, can recognize multiple markers such as EpCAM and Vimentin, and realizes efficient capture of heterogeneous CTCs. The dissociation and recovery module uses a low-temperature buffer system and a cleavable cross-linking agent to release cells gently. The cell protection module maintains the integrity and activity of the cell membrane during the separation process. The method of the present application can ensure the capture efficiency while obtaining high-activity CTCs, and is suitable for single-cell sequencing, drug sensitivity analysis, organoid culture and patient-derived cell line construction and other preclinical research.

The present invention relates to a therapeutic composition for inhibiting the activity of a systemic sclerosis waveform protein variant using a STAT6 inhibitor, and has been confirmed that the STAT6 inhibitor inhibits the expression of fibrotic T cells and M2 macrophages, which are immune cells associated with systemic sclerosis, increases the expression of Treg, and inhibits the expression of fibrotic T cells and M2 macrophages, which are immune cells associated with systemic sclerosis. It has been confirmed that the expression of TGF-beta, Col1a1, and alpha-SMA, which are fibrosis factors associated with systemic sclerosis, is inhibited. Moreover, it has been confirmed that the expression of cell surface waveform protein, which is a waveform protein variant associated with systemic sclerosis, is reduced in skin tissue and lung tissue, and it has been confirmed that the waveform protein variant can be regulated. In addition, the presence of pSTAT6-expressed CD8T cells is confirmed in fibrotic tissues, and the expression of pSTAT6-expressed CD8T positive cells is confirmed to be regulated by administration of an STAT6 inhibitor. The STAT6 inhibitor also has been confirmed to inhibit the tissue fibrosis of systemic sclerosis in which the antigen-specific disease activity is increased in an animal model with increased waveform protein-specific disease activity, and to inhibit the expression of CD8-positive TRM expressed by an IL-17 cytokine capable of inducing inflammation and fibrosis, which is a systemic sclerosis cause cell.

Disclosed herein are chimeric antigen receptors targeting cVIM on the surface of cancer cells. Also disclosed are compositions comprising CARs targeting cVIM and methods of using these compositions to treat cancer and / or slowing disease progression in a subject.

The present invention discloses the application of vimentin in the preparation of a drug for the treatment of Guangzhou angiostrongylus disease. The present invention constructs a mouse infection model of Guangzhou angiostrongylus disease, and finds that the level of vimentin and its phosphorylation level in the brain tissue of mice in the late stage of infection are significantly increased, and the permeability of the blood-brain barrier is significantly increased. After knocking out vimentin using the Vimentin-knockout mouse model, it was found through magnetic resonance imaging and Evans blue experiments that the degree of blood-brain barrier damage in infected mice was effectively alleviated, the expression of AQP4, a molecule related to blood-brain barrier damage, was significantly reduced, and the expression of tight junction protein occludin was significantly increased. The research results of the present invention show that vimentin is a key regulatory factor involved in the destruction of the blood-brain barrier of Guangzhou angiostrongylus disease, and downregulating vimentin can play a role in the treatment of Guangzhou angiostrongylus disease. Vimentin can be used as a therapeutic target for Guangzhou angiostrongylus disease for the preparation or screening of drugs for the treatment of Guangzhou angiostrongylus disease.

The invention relates to the technical field of medicine, in particular to application of tetrandrine citrate and analogues thereof in preparation of medicine for treating pulmonary fibrosis, safety is improved, a tetrandrine citrate solution is dosed through airway atomization, and the weight loss degree of pulmonary fibrosis rats is relieved; the lung coefficient of the pulmonary fibrosis rats is reduced; the phenomena of alveolar gap reduction, alveolar wall thickening, inflammatory cell infiltration and the like are relieved; the contents of IL-1beta, TNF-alpha, alpha-SMA and Vimentin in lung tissues, alveolar lavage fluid and serum of the rats with pulmonary fibrosis are reduced, and the content of SOD (superoxide dismutase) is increased; the proliferation of A549 cells is inhibited; the contents of COL-I, FN and Vimentin in a pulmonary fibrosis cell model are reduced.

The present invention belongs to the technical field of biochemical testing, and specifically provides a streptavidin-coupled antibody capture CTC detection kit and a preparation method thereof, wherein the kit includes components such as biotin-modified EpCAM monoclonal antibody and Vimentin monoclonal antibody, a pretreatment agent, a separation liquid, a fixative, a permeabilization agent, a blocking agent, a fluorescent staining liquid and a microfluidic chip. The bottom layer of the chip channel is solidified with streptavidin, and the upper layer is an asymmetric herring bone structure, which can enhance the binding efficiency between cells and antibodies. The kit achieves efficient capture of CTCs of different phenotypes through multi-antibody composite recognition, and combines immunofluorescence staining for multi-marker detection, with both sensitivity and specificity. The method has a standardized process flow and stable components, and is suitable for the enrichment and analysis of CTCs in clinical samples.

The invention discloses application of hAMSCs injected in different modes in preparation of drugs for improving pulmonary fibrosis EMT and apoptosis, and relates to the technical field of medicines. The hAMSCs provided by the invention are the third generation to the fifth generation of hAMSCs obtained by subculture, the hAMSCs highly express MSCs symbolic protein CD90, CD105, CD44 and CD73, and the hAMSCs lowly express CD11b, CD34, CD45 and CD19. The invention has proved that the expression of an epithelial marker E-cadherin can be increased by intratracheal or caudal vein injection of hAMSCs, and the expression of an interstitial marker vimentin is inhibited at the same time, so that the occurrence and development of IPF are prevented. A new thought is provided for preventing and preparing the IPF medicine.

This cell line is derived from a fish belonging to the family Anguillidae, expresses at least one selected from the group consisting of vimentin, CD29, CD73, and CD105, and has ability to accumulate fat. Also provided is a method for producing cells in which fat accumulates, the method involving a step for culturing the cell line derived from a fish belonging to the family Anguillidae in a culture medium, and causing fat to accumulate in the cells. Also provided is a fat production kit comprising the cell line derived from a fish belonging to the family Anguillidae, a fat accumulation culture medium, and a culture container.

The present application relates to a fluorescent immunochromatographic test strip for detecting rheumatoid arthritis. The test strip comprises a sample loading area, a detection area and a water absorption area, the detection area comprising a first sub-detection area having affixed a mutant citrullinated vimentin, a second sub-detection area having affixed a cyclic citrullinated peptide, and a third sub-detection having affixed a denatured human IgG.